A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Condition:   Dermatitis, Atopic Intervention:   Drug: BI 655130 Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions: It seems that the colonisation of the lesioned skin, healthy skin and the anterior nares by S. aureus is related with higher tIgE serum concentration, which translates to more severe course of the disease. Significantly increased SEA-IgE and SEB-IgE concentrations were observed in the patients whose tIgE serum concentration was statistically higher. PMID: 31616226 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Capsule Summary: Ruxolitinib cream improved Eczema Area Severity Index and Investigator ’s Global Assessment responses in patients with atopic dermatitis (AD), with rapid, sustained improvement in itch. Ruxolitinib cream may offer a novel and effective treatment for AD.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: The prevalence of p-phenylenediamine allergy remains high among patients with contact eczema. Risk factors for p-phenylenediamine contact allergy are consistent with previous reports. PMID: 31627850 [PubMed - as supplied by publisher]
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Authors: Tags: Actas Dermosifiliogr Source Type: research
CONCLUSIONS: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candida...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children. J Drugs Dermatol. 2019;18(10):1038-1045. PMID: 31584783 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Conditions:   Atopic Dermatitis;   Atopic Eczema Interventions:   Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo;   Drug: Protopic, tacrolimus ointment 0.1% Sponsors:   Jacob Thyssen;   LEO Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
LOS ANGELES, Oct. 3, 2019 -- (Healthcare Sales &Marketing Network) -- Turn Therapeutics™, Inc., a Los Angeles-based pharmaceutical and medical device company, has announced the closing of its fully-subscribed series B financing. The capital raised will f... Biopharmaceuticals, Dermatology, Venture Capital Turn Therapeutics, AtopX, Eczema Emulsion, PermaFusion
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
CBS News Miami anchor Frances Wang, 27, was diagnosed this year with perioral dermatitis, a skin condition that occurs due to prolonged use of topical steroid creams for her eczema.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Dermatitis | Dermatology | Eczema | Research | Study